MFSD2A expression predicts better prognosis in gastric cancer

Major facilitator superfamily domain containing-2A (MFSD2A) is reported to correlated with some tumors, but its clinical significance in gastric cancer (GC) is still unknown. The expression of MFSD2A and CD34 were examined on tissue microarrays of 170 set of GC and adjacent normal tissue (ANT) by immunohistochemistry. The relationship of MFSD2A with microvessel density (MVD) and clinicopathological characteristics was also investigated. MFSD2A expression is lower in GC tissue (35.3%) than in ANT (78.2%, P < 0.01). Mean MVD was higher in cancer tissue (49.7 ± 5.46) than in ANT (19.3 ± 2.19, P < 0.01), and higher in MFSD2A− GC (56.5 ± 7.27), than in MFSD2A+ GC (24.8 ± 4.31, P < 0.01). MFSD2A expression was significantly higher in moderately/well differentiated GC (47.4%) than in poorly differentiated GC (25.0%, P < 0.01) and in early-stage GC (46.4%) than in advanced GC (27.7%, P = 0.012). Patients with MFSD2A+ specimens (n = 60) had significantly better prognoses than the MFSD2A− group (n = 110; P < 0.0001). These results suggest that MFSD2A might affect angiogenesis and inhibit GC development and progression. MFSD2A may help predict prognosis and could be a therapeutic target in GC.